Mesmulogene ancovacivec

DB06584InvestigationalVaccines

A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for... Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens.

Primary indication
Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.Curator reviewed
Also known as
MVA-Muc1-IL2
Code names
TG 4010

Resolves to

Compound
UNIIWQQ9XZH2CCCAS350485-85-7
Targets
P15941MUC1P60568IL2

What you can answer from here — as of October 27, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
289Drug interactionsStructured to mechanism, not free text
Sign in
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Mesmulogene ancovacivec, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In